Overview

A Trial of SHR-7367 in Subjects With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-7367 in subjects with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Hengrui Pharmaceutical Co., Ltd.